HEALTH CARE CONGRESSIONAL "MAINSTREAM COALITION" MEETING WEEKLY
Executive Summary
HEALTH CARE CONGRESSIONAL "MAINSTREAM COALITION" MEETING WEEKLY to find areas of commonality among the managed competition bills sponsored by Rep. Cooper (D-Tenn.) and Sen. Breaux (D-La.) and other proposals seen as more "centrist" than the Clinton Administration's plan. For example, Cooper, Breaux and their cosponsors may support a mandate that individuals purchase health care coverage, a mandate included in a proposal by Sen. Chafee (R- R.I.), congressional aides reported Nov. 11. Chafee is expected to introduce formal legislation on Nov. 17. The self-styled "mainstream coalition" includes Reps. Johnson (R-Conn.), Stenholm (D-Texas), Grandy (R-Iowa), Thomas (R-Calif.) and Andrews (D-Texas), and Sens. Boren (D-Okla.), Lieberman (D- Conn.), Kerrey (D-Neb.), Durenberger (R-Minn.), Danforth (R-Mo.), Bond (R-Mo.), Cohen (R-Maine), Domenici (R-N.M.), Stevens (R- Alaska) and Bennett (R-Utah). The primary emphasis of the meetings has been a concern with various aspects of the Clinton Administration's proposal, including its offering of universal coverage before savings are achieved under reform and its provision of benefits covering prescription drugs, long-term care and early retirees. Staffers are planning to work out various compromise scenarios over the Thanksgiving recess and prepare them for review by coalition members. Key issues for consideration include the size of health insurance purchasing cooperatives, whether to have competing HIPCs, specific coverage cut-offs for low-income individuals and the size of risk pools.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth